ABVC

ABVC Biopharma Inc

Add to Watchlist

Advanced Chart

3.070

+0.06(1.993%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.105

Open

2.950

VWAP

2.96

Vol

231.88K

Mkt Cap

51.49M

Low

2.910

Amount

685.59K

EV/EBITDA(TTM)

Total Shares

12.05M

54.46M

EV/OCF(TTM)

P/S(TTM)

76.82

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2023Q4

0.00

-100%

Estimates Revision

Stock Price

Go Up

+236.99%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for ABVC Biopharma Inc (ABVC.O) is -0.65, compared to its 5-year average forward P/E of -6.04. For a more detailed relative valuation and DCF analysis to assess ABVC Biopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.04

Current PE

-0.65

Overvalued PE

1.63

Undervalued PE

-13.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

132.20

Current PS

13.71

Overvalued PS

418.31

Undervalued PS

-153.91

Financials

Annual

Quarterly

FY2025Q1

YoY :

-100.00%

0.00

Total Revenue

FY2025Q1

YoY :

-75.58%

-693.01K

Operating Profit

FY2025Q1

YoY :

-67.75%

-944.19K

Net Income after Tax

FY2025Q1

YoY :

-79.31%

-0.06

EPS - Diluted

FY2025Q1

YoY :

-43.52%

-539.83K

Free Cash Flow

FY2025Q1

YoY :

-100.00%

N/A

Gross Profit Margin - %

FY2025Q1

YoY :

-98.10%

-274.04

FCF Margin - %

FY2025Q1

YoY :

-100.00%

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ABVC News & Events

Events Timeline

2024-12-11 (ET)

2024-12-11

05:37:58

ABVC BioPharma receives $200,000 cash payment from OncoX

2024-11-14 (ET)

2024-11-14

08:03:15

ABVC BioPharma reports Q3 EPS (2c) vs (82c) last year

2024-10-22 (ET)

2024-10-22

08:48:07

ABVC BioPharma receives $50,000 in incremental licensing fees

News

9.0

2024-12-19Newsfilter

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

7.5

2024-12-11Newsfilter

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

7.5

2024-12-11SeekingAlpha

ABVC BioPharma gets $200K in cash from OncoX BioPharma

People Also Watch

BioNexus Gene Lab Corp

MicroCloud Hologram Inc

Arcadia Biosciences Inc

Plus Therapeutics Inc

Future Fintech Group Inc

2.740

USD

-1.79%

FAQ

What is ABVC Biopharma Inc (ABVC) stock price today?

The current price of ABVC is 3.07 USD — it has increased 1.99 % in the last trading day.

ABVC

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ABVC News & Events

Events Timeline

News

People Also Watch

FAQ

What is ABVC Biopharma Inc (ABVC) stock price today?

What is ABVC Biopharma Inc (ABVC)'s business?

What is the price predicton of ABVC Stock?

What is ABVC Biopharma Inc (ABVC)'s revenue for the last quarter?

What is ABVC Biopharma Inc (ABVC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for ABVC Biopharma Inc (ABVC)'s fundamentals?

How many employees does ABVC Biopharma Inc (ABVC). have?

What is ABVC Biopharma Inc (ABVC) market cap?